Jiabin Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiabin Cai has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Jinhu Wang
Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
12 shared publications - Ting Tao
Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases, Hangzhou, China.
12 shared publications - Dongfang Lu
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Jinkai Peng
Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Children’s Hospital Zhejiang University School of Medicine, Hangzhou, China
11 shared publications - Lifeng Zhang
Department of Oncology Surgery, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China
11 shared publications - Shouhua Zhang
Department of General Surgery, Jiangxi Provincial Children’s Hospital, The Affiliated Children’s Hospital of Nanchang Medical College, Nanchang, China
11 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in Asian Journal of Surgery
Visual acuity and axial length trajectories in children with early-onset high myopia receiving repeated low-level red light therapy
- 29 October 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessVisual acuity and axial length trajectories in children with early-onset high myopia receiving repeated low-level red light therapy
- Open Access
- 18 March 2026
- Published by Elsevier in Asian Journal of Surgery
Congenital hepatoblastoma with rapid progression to synchronous brain and ocular metastases: A case report
- 18 March 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessCongenital hepatoblastoma with rapid progression to synchronous brain and ocular metastases: A case report
- Open Access
- 3 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71666
Integrative Genomic Profiling of Pediatric Solid Tumors Reveals Clinically Relevant Variants and Chromosomal Arm Aneuploidies Signatures
Background: Pediatric malignancies have emerged as the leading cause of disease‐related mortality in children, exhibiting distinct etiological and molecular characteristics compared to adult cancers. Despite advances in genomic profiling, the molecular landscape of pediatric solid tumors, particularly in Chinese populations, remains undercharacterized. Methods: Through targeted next‐generation sequencing of 94 pediatric solid tumors, we systematically analyzed single nucleotide variants, short insertions/deletions, copy number variations, and chromosomal arm‐level aneuploidy, with particular emphasis on subtype‐specific genomic architectures. Results: Tumor relevant variants were identified in 74.5% of cases, comprising germline predisposition variants (17.0%) with higher prevalence in blastomas and somatic mutations (71.3%). Remarkably, 58.5% harbored therapeutic targets or guideline‐recommended biomarkers, providing molecular rationales for precision therapeutic strategies. Key findings revealed tumor‐type specific chromosomal instability patterns: sarcoma‐characteristic chromosome 8 gains, neuroblastoma‐enriched 17q amplifications, and TP53 mutations co‐occurring with 1q gains—a profile divergent from adult malignancies. Conclusion: This study establishes the most comprehensive genomic atlas of Chinese pediatric solid tumors to date, delineating subtype‐specific oncogenic variants and chromosomal instability signatures. Our findings advance the understanding of childhood cancer pathogenesis and provide a framework for molecularly guided clinical decision‐making.
- 3 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71666
Open AccessIntegrative Genomic Profiling of Pediatric Solid Tumors Reveals Clinically Relevant Variants and Chromosomal Arm Aneuploidies Signatures
Background: Pediatric malignancies have emerged as the leading cause of disease‐related mortality in children, exhibiting distinct etiological and molecular characteristics compared to adult cancers. Despite advances in genomic profiling, the molecular landscape of pediatric solid tumors, particularly in Chinese populations, remains undercharacterized. Methods: Through targeted next‐generation sequencing of 94 pediatric solid tumors, we systematically analyzed single nucleotide variants, short insertions/deletions, copy number variations, and chromosomal arm‐level aneuploidy, with particular emphasis on subtype‐specific genomic architectures. Results: Tumor relevant variants were identified in 74.5% of cases, comprising germline predisposition variants (17.0%) with higher prevalence in blastomas and somatic mutations (71.3%). Remarkably, 58.5% harbored therapeutic targets or guideline‐recommended biomarkers, providing molecular rationales for precision therapeutic strategies. Key findings revealed tumor‐type specific chromosomal instability patterns: sarcoma‐characteristic chromosome 8 gains, neuroblastoma‐enriched 17q amplifications, and TP53 mutations co‐occurring with 1q gains—a profile divergent from adult malignancies. Conclusion: This study establishes the most comprehensive genomic atlas of Chinese pediatric solid tumors to date, delineating subtype‐specific oncogenic variants and chromosomal instability signatures. Our findings advance the understanding of childhood cancer pathogenesis and provide a framework for molecularly guided clinical decision‐making.
- 12 January 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2369-2376
Establishment and characterization of a testicular yolk sac tumor PDX model
Objective To establish a patient-derived xenograft (PDX) model of testicular yolk sac tumor (TYST) that faithfully recapitulates the histopathological and molecular features of the primary tumor, thereby providing a robust pre-clinical platform for studying yolk sac tumor pathogenesis and evaluating novel therapeutics. Methods Patient-derived TYST tumor tissues were implanted subcutaneously in the right scapular region of immunodeficient mice (NPG and BALB/c nude strains) to generate a PDX model. Engrafted tumors were serially passaged and characterized by hematoxylin and eosin (H&E) staining, immunohistochemistry for AFP and SALL4, and PCR-based species identification to exclude murine lymphoma. The anti-tumor efficacy of the JEB regimen (carboplatin, etoposide, and bleomycin) was assessed using both in vivo experiments with the PDX model and ex vivo experiments utilizing the hydrogel-embedded histoculture drug sensitivity test (HDST). Results The patient-derived TYST tumor tissues exhibited higher tumorigenicity in NPG and BALB/c nude mice, maintaining stability through serial passaging. H&E staining confirmed preservation of characteristic yolk sac morphology, including Schiller–Duval bodies. Immunohistochemical analysis demonstrated consistent expression of AFP and SALL4 in PDX tumors, mirroring the diagnostic profile of the original specimen. PCR results confirmed the human origin of the xenografts and ruled out spontaneous murine lymphomas. HDST assays revealed marked sensitivity to the JEB regimen, which was corroborated in vivo: JEB treatment induced significant tumor regression without causing clinically relevant body weight loss. Conclusion We successfully established a TYST PDX model that retains tissue structure and protein expression signature of the patient’s tumor tissue. Furthermore, this PDX model demonstrates high sensitivity to standard JEB chemotherapy and represents a valuable resource for translational research in pediatric germ cell tumors.
- 12 January 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (6) , 2369-2376
Establishment and characterization of a testicular yolk sac tumor PDX model
Objective To establish a patient-derived xenograft (PDX) model of testicular yolk sac tumor (TYST) that faithfully recapitulates the histopathological and molecular features of the primary tumor, thereby providing a robust pre-clinical platform for studying yolk sac tumor pathogenesis and evaluating novel therapeutics. Methods Patient-derived TYST tumor tissues were implanted subcutaneously in the right scapular region of immunodeficient mice (NPG and BALB/c nude strains) to generate a PDX model. Engrafted tumors were serially passaged and characterized by hematoxylin and eosin (H&E) staining, immunohistochemistry for AFP and SALL4, and PCR-based species identification to exclude murine lymphoma. The anti-tumor efficacy of the JEB regimen (carboplatin, etoposide, and bleomycin) was assessed using both in vivo experiments with the PDX model and ex vivo experiments utilizing the hydrogel-embedded histoculture drug sensitivity test (HDST). Results The patient-derived TYST tumor tissues exhibited higher tumorigenicity in NPG and BALB/c nude mice, maintaining stability through serial passaging. H&E staining confirmed preservation of characteristic yolk sac morphology, including Schiller–Duval bodies. Immunohistochemical analysis demonstrated consistent expression of AFP and SALL4 in PDX tumors, mirroring the diagnostic profile of the original specimen. PCR results confirmed the human origin of the xenografts and ruled out spontaneous murine lymphomas. HDST assays revealed marked sensitivity to the JEB regimen, which was corroborated in vivo: JEB treatment induced significant tumor regression without causing clinically relevant body weight loss. Conclusion We successfully established a TYST PDX model that retains tissue structure and protein expression signature of the patient’s tumor tissue. Furthermore, this PDX model demonstrates high sensitivity to standard JEB chemotherapy and represents a valuable resource for translational research in pediatric germ cell tumors.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S3. Copy-number Z-score of ctDNA samples from pNT patients and healthy controls.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
The diagnostic performance of pNT-UCAD evaluated based on TFx in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Customized pNT-UCAD workflow designed for diagnosis, risk stratification, and treatment response evaluation of pediatric neuroblastic tumor. GN, ganglioneuroma; GNB, ganglioneuroblastoma; NB, neuroblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Statistical analysis of TFx between various clinicopathologic groups in pNTs.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors
Table S1. The demographic characteristics of patients.